Noriyuki Masuda - Concepedia

Author

Noriyuki Masuda

Kitasato University

Also Known As

N Masuda, NORIYUKI MASUDA, Noriyuk Masuda, Noriyuki MASUDA, Noriyuki Masuda

247

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

Kitasato University Osaka Prefectural Medical Center Kitasato University Hospital Kindai University Tokyo Metropolitan Komagome Hospital

About

Noriyuki Masuda is an author at Kitasato University specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	45	1.2K
2	Health Sciences	9	9	226
3	Natural Sciences	3	3	43
4	Engineering	2	2	48
5	Social Sciences	2	2	44

Noriyuki Masuda

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer Riichiroh Maruyama, Yutaka Nishiwaki, Tomohide Tamura, Journal of Clinical Oncology	2008	364
Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301 Sayaka Onoda, Noriyuki Masuda, Takashi Seto, Journal of Clinical Oncology	2006	226
Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors Taroh Satoh, Isamu Okamoto, Masaki Miyazaki, Clinical Cancer Research	2009	175
Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer Terufumi Kato, Noriyuki Masuda, Yoichi Nakanishi, Lung Cancer	2016	104
Deconjugation of Bile Salts by <i>Bacteroides</i> and <i>Clostridium</i> Noriyuki Masuda Microbiology and Immunology BiochemistryResting CellsBacteriologyBiotechnologyMicrobial Physiology	1981	93
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group Kenichi Inoue, Kazuhiko Nakagami, Mitsuhiro Mizutani, Breast Cancer Research and Treatment Breast OncologyMedicinePhase Iii TrialClinical TrialsBreast Cancer	2009	89
Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung Tomoya Fukui, Koji Tsuta, Koh Furuta, Cancer Science	2007	80
EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance Shi‐Xu Jiang, Kazuya Yamashita, Michiko Yamamoto, International Journal of Cancer	2008	79
Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas Ryo Nagashio, Yuichi Sato, Toshihide Matsumoto, Lung Cancer Pulmonary AdenocarcinomasMedicinePathologyCancer GenomicsBronchial Neoplasm	2009	72
Enhanced Antitumor Efficacy of a Combination of CPT‐11, a New Derivative of Camptothecin, and Cisplatin against Human Lung Tumor Xenografts Shinzoh Kudoh, Minoru Takada, Noriyuki Masuda, Japanese Journal of Cancer Research	1993	71

Page 1